/
MAIA
$1.48+$0.07 (+4.96%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$85.7M
61M shares
52-week range
$0.87 – $3.19
26% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
7.05%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-2.98
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $1.9M | $1.4M | $3.5M | $8.9M | $11.1M | $10.0M | $14.55B |
| Operating income | −$6.9M | −$7.0M | −$7.8M | −$16.2M | −$20.2M | −$17.0M | −$24.3M |
| EBITDA | $0 | $0 | −$11.8M | −$15.8M | −$19.8M | −$23.3M | −$22.4M |
| Net income | −$6.5M | −$6.6M | −$12.5M | −$15.8M | −$19.8M | −$23.3M | −$22.4M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.61 | -0.62 | -1.18 | -1.70 | -1.49 | -1.05 | -0.70 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $65M | $-0.52 | $-0.52–$-0.52 | 1 |
| 2027 | $66M | $1.12 | $1.12–$1.12 | 1 |
| 2028 | $402M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$269.53
Price
$1.48
Implied upside
+18112%
Peer comparison
MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
www.maiabiotech.com- Employees
- 13
- IPO / List date
- Jul 28, 2022
- HQ
- CHICAGO, IL
Held by traders on TradeandTell
No one on the platform currently holds MAIA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MAIA as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MAIA yet.
